Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING
August 30 2022 - 7:25AM
Hofseth Biocare ASA: COMPLETED EXTRAORDINARY GENERAL MEETING
The Extraordinary General Meeting in Hofseth BioCare ASA was
held at the premises of the Company in Ålesund, Norway today
Tuesday 30 August 2022.
All matters were approved according to the proposals in the
notice. Please find the minutes from the general meeting
attached.
For further information, please contact: Jon Olav Ødegård, CEO
of Hofseth BioCare ASA Phone: +47 93632966 E-mail:
joo@hofsethbiocare.no
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health ingredient supplier
and an incubator for new pharmaceutical drug leads. Research is
ongoing to identify the individual elements within its ingredients
that modulate inflammation and the immune response with
pre-clinical studies ongoing in multiple clinics and university
research labs. Lead clinical and pre-clinical candidates are
focused on developing an oral treatment for inflammatory disease
driven by eosinophils (a type of white blood cell). Clinical trial
work with the oil is ongoing to ameliorate lung inflammation in
eosinophilic asthma and COPD ("smokers lung") as well as in
COVID.
Other leads are focused on the protection of the Gastro-
Intestinal (GI) system against inflammation (including ulcerative
colitis and the orphan condition necrotizing enterocolitis) and
using peptide fractions of salmon protein hydrolysate (SPH also
known as 'ProGo') as a Medical Food to help treat age-related
Sarcopenia, and as a treatment for Iron Deficiency Anemia. The
company is founded on the core values of sustainability, optimal
utilization of natural resources and full traceability. Through an
innovative hydrolysis technology, HBC can preserve the quality of
the lipids, proteins and calcium from fresh salmon off-cuts.
Hofseth BioCare's headquarters are in Ålesund, Norway with
branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo
Alto.
This information is subject to the disclosure requirements
pursuant to Section 5-12 of the Norwegian Securities Trading
Act
Hofseth Biocare Asa (LSE:0Q6H)
Historical Stock Chart
From Jan 2025 to Feb 2025
Hofseth Biocare Asa (LSE:0Q6H)
Historical Stock Chart
From Feb 2024 to Feb 2025